AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15108771
Drug: Standard tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tacrolimus (trough levels of 10-15 ng/mL) plus reduced sirolimus (trough levels of 5-10 ng/mL) (Group I)
Trial: 7506878
Drug: Aspartame (APM)
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (APM) 34 mg/kg single morning dose
Trial: 6627697
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg)
Trial: 22298375
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (negative control)
Trial: 21267525
Drug: n‐3 LCPUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 LCPUFA supplementation (2.5 g/day, with 1.67 grams of EPA and 0.83 grams of DHA)
Trial: 17941876
Drug: Nateglinide +
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide + Metformin
Trial: 3911096
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg guanfacine hydrochloride (Estulic)
Trial: 3911096
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg guanfacine hydrochloride (Estulic)
Trial: 3911096
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg clonidine (Catapres)
Trial: 3911096
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg clonidine (Catapres)
Trial: 29505517
Drug: Control (fasting,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (fasting, decompression, intravenous somatostatin)
Trial: 26909012
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment with ibuprofen
Trial: 788655
Drug: Non-antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antibiotic treatment
Trial: 1978612
Drug: Esmolol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1.5 mg/kg
Trial: 9084524
Drug: Esmolol 2
RxNorm normalized name: esmolol 20 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 2 mg/kg
Trial: 19273696
Drug: INT0116 (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INT0116 (standard treatment)
Trial: 8316346
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 450-750 mg/day
Trial: 27958690
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) 300 µg, two injections prior to BM-MNC transplantation
Trial: 26149149
Drug: Short-term pressure
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term pressure gauge training (G group)
Trial: 19260323
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment
Trial: 22352262
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid plus basic treatment
Trial: 7051246
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ; 160 mg of TMP and 800 mg of SMZ) twice daily for 21 days
Trial: 21915572
Drug: PTH 1-84
RxNorm normalized name: PTH(1-84)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH 1-84 (100 µg once daily)
Trial: 14687899
Drug: No-drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-drug treatment
Trial: 18287591
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (1 mg)
Trial: 6134490
Drug: Alclofenac 1
RxNorm normalized name: Acéclofénac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alclofenac 1 g 3 or 4 times daily
Trial: 6134490
Drug: Gold injections
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold injections 50 mg weekly intramuscularly to 1 g then 50 mg monthly
Trial: 29350663
Drug: Tailored medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored medical support including translated booklets, weekly visits, family-guides, and interpreter-supported clinic visits (Group 1)
Trial: 22182667
Drug: Family-focused treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused treatment for prodromal youth (6-month, 18-session intervention)
Trial: 21510531
Drug: Buffy coat
RxNorm normalized name: Leucocyte buffy coat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffy coat (mesenchymal stem cell concentrate) injection along with arthroscopic debridement
Trial: 16135173
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline (200 mg in 200 mL saline) for 2 hours
Trial: 16135173
Drug: Saline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (200 mL)
Trial: 12424551
Drug: Stimulant medications
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medications (6-month trial)
Trial: 15960563
Drug: Sertraline (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50-100 mg/day)
Trial: 8477412
Drug: Fluoxetine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20-40 mg/day)
Trial: 6786953
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg copper daily (fixed dose)
Trial: 6786953
Drug: Copper requirements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper requirements for total parenteral nutrition
Trial: 6786953
Drug: Copper requirements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper requirements for total parenteral nutrition with diarrhea or increased fluid loss
Trial: 6786953
Drug: Urinary copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary copper excretion
Trial: 31636000
Drug: 2D Gaussian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2D Gaussian probability density function of rectal motion and wall thickness (2D pdfM&TW)
Trial: 31636000
Drug: Probability density
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probability density functions of rectal deformation (DW), rectal dose distribution (RM), and changes in rectal wall thickness (TW)
Trial: 31636000
Drug: Gaussian mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaussian mixture distributions for rectal wall thickness
Trial: 26527863
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of dicloxacillin sodium (0.25, 0.5, 1.0, and 2.0 g)
Trial: 26527863
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of dicloxacillin sodium (0.25 or 0.5 g every 6 hours for 3 days)
Trial: 11132503
Drug: Wand injections
RxNorm normalized name: CLEANSER,PROSTHETIC THE LINER WAND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wand injections
Trial: 11132503
Drug: Traditional palatal
RxNorm normalized name: malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional palatal injection
Trial: 20855349
Drug: Psilocybin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (high doses)
Trial: 17209189
Drug: Weekly multiple-micronutrient
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly multiple-micronutrient foodLET providing twice the RNI (WMM)
Trial: 17209189
Drug: Daily 10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 10-mg Fe foodLET (DI)
Trial: 11531839
Drug: Calcipotriol 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 0.05 mg g(‐1) cream applied 1 hour before PUVA treatment
Trial: 11531839
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied 1 hour before PUVA treatment
Trial: 16412037
Drug: Regional interventional
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regional interventional chemotherapy (infused directly into the common hepatic artery)
Trial: 16412037
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (via peripheral vein)
Trial: 8216438
Drug: LNC‐834 (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNC‐834 (350 mg of hydrated salt corresponding to 226 mg anhydrous free base each) administered twice daily for 9 days, with warfarin (0.36 +/- 0.03 mg/kg) on the 4th day
Trial: 27299458
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of Life Assessment based on Traditional Chinese Medicine (QLASTCM‐Ga)
Trial: 24072699
Drug: Resveratrol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (1000 mg daily for week 1 followed by 2000 mg daily for week 2)
Trial: 20495134
Drug: ABT-107 single
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-107 single oral doses (1, 3, 10, 30, 60, 80, and 100 mg)
Trial: 20495134
Drug: ABT-107 20-mg
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-107 20-mg single dose (effect of food)
Trial: 19054806
Drug: Sequential Organ
RxNorm normalized name: argan oil
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Organ Failure Assessment score
Trial: 29231568
Drug: Drug-spreading moxibustion
RxNorm normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-spreading moxibustion
Trial: 29231568
Drug: Meloxicam (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (7.5 mg once a day for three days)
Trial: 15355747
Drug: COX-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COX-2 inhibitors
Trial: 17923032
Drug: Selective COX-2
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective COX-2 inhibitors
Trial: 22442673
Drug: Standard decentralised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard decentralised psychiatric treatment
Trial: 20136164
Drug: Fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibric acid + moderate-dose statin
Trial: 18376348
Drug: Metoprolol (0.5-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (0.5-1.5 mg/kg/d)
Trial: 16045525
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (600 microg, followed by 400 microg)
Trial: 12477581
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg IV (Group D)
Trial: 12477581
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of droperidol 1.25 mg IV and ondansetron 4 mg IV (Group D+O)
Trial: 12477581
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (Combination of droperidol and ondansetron)
Trial: 7135113
Drug: Caffeine solution
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine solution (5 mg caffeine/kg body weight) ingested 1 hour prior to running
Trial: 27723261
Drug: Mud-bath therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud-bath therapy (MBT) in addition to usual treatment
Trial: 19750959
Drug: Individualized physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized physical rehabilitation (IPR) consisting of four physical therapy sessions plus three telephone calls
Trial: 24954156
Drug: Antidepressant treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatments
Trial: 9521955
Drug: AMOX/CLAV (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMOX/CLAV (40 mg/kg in 3 divided doses daily)
Trial: 8041534
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy (continuous conjugated equine estrogens at 0.625 mg/day with sequential dl-norgestrel at 0.15 mg/day for 12 days each cycle)
Trial: 8041534
Drug: Transdermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapy (patches delivering continuous 17 beta-estradiol at 0.05 mg/day with sequential norethindrone acetate at 0.25 mg/day for 14 days each cycle)
Trial: 30641096
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment continued after meeting switching criteria at month 3
Trial: 30641096
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment continued after meeting switching criteria at month 6
Trial: 23062021
Drug: Yoga group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga group (50-60 minutes of yogic practices daily for 42 days)
Trial: 11475562
Drug: Salbutamol (Steri-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (Steri-Neb Salamol 2.5 mg) nebulization
Trial: 31713297
Drug: Topical tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tamoxifen gel
Trial: 31713297
Drug: Oral tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tamoxifen 10 mg OD
Trial: 28366818
Drug: Adjunctive photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive photodynamic therapy (PDT)
Trial: 23560645
Drug: Adjunctive local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive local drug delivery (LDD) with minocycline microspheres
Trial: 22077420
Drug: Iseganan HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Iseganan (DB16010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iseganan HCl 9 mg/3 ml, administered as a swish and swallow solution, six times daily for 21-28 days.
Trial: 20384753
Drug: KTP laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTP laser treatment
Trial: 16020212
Drug: IPL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL treatment
Trial: 15780536
Drug: 0.025 mg
RxNorm normalized name: lisuride 0.025 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg estradiol and 0.125 mg norethisterone acetate daily
Trial: 11808971
Drug: parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: parecoxib sodium 40 mg b.i.d. for 7 days
Trial: 11808971
Drug: ketorolac 15
RxNorm normalized name: ketorolac 15.75 mg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 15 mg q.i.d. for 5 days
Trial: 6967580
Drug: Rifampin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (20 mg/kg for four days)
Trial: 6967580
Drug: Rifampin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (20 mg/kg for four days) after ampicillin treatment failure
Trial: 28855078
Drug: Guided de-escalation
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided de-escalation group (1 week prasugrel followed by 1 week clopidogrel and PFT-guided maintenance therapy)
Trial: 25877813
Drug: carnitine‐orotate complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carnitine‐orotate complex (824 mg, three times daily)
Trial: 16398425
Drug: Pingxiao capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pingxiao capsule (PXC) plus endocrinotherapy (ET)
Trial: 12188940
Drug: High-dose mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose mannitol (approximately 1.4 g/kg)
Trial: 12188940
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose mannitol (approximately 0.7 g/kg)
Trial: 345433
Drug: Heparin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin added to dialysis solution
Trial: 345433
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin added to dialysis solution
Trial: 22023022
Drug: Concurrent alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent alcohol and smoking treatment
Trial: 17688969
Drug: docetaxel/gemcitabine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel/gemcitabine combination therapy
Trial: 11507733
Drug: Prostane (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostane (herbal formulation) at a dose of two tablets a day for 1 year
Trial: 11507733
Drug: Prostane (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostane (herbal formulation)
Trial: 7851270
Drug: IDDM patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDDM patients with altered urinary albumin excretion rate (AER > or = 20 micrograms/min)
Trial: 12648191
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (LD) remifentanil (0.13 microg kg‐1 x min‐1)
Trial: 12648191
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (HD) remifentanil (0.39 microg kg‐1 x min‐1)
Trial: 16114784
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg t.i.d.
Trial: 3534852
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg t.i.d.
Trial: 10517426
Drug: Oral oseltamivir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oseltamivir (100 mg once daily, 100 mg twice daily)
Trial: 25043337
Drug: RBP-7000 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBP-7000 at 60 mg and 90 mg
Trial: 22932339
Drug: GSK1034702 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1034702 (8 mg)
Trial: 17598697
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation tablets
Trial: 17598697
Drug: Melcam 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melcam 15 mg tablets (test preparation)
Trial: 23571785
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide cream (TA)
Trial: 14524485
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (354 ml/day)
Trial: 14524485
Drug: Apple juice
RxNorm normalized name: apple juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple juice (354 ml/day)
Trial: 1410946
Drug: Manual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual treatment (manipulation, specific mobilization, muscle stretching, auto-traction, cortisone injections)
Trial: 2412056
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of Ketanserin.
Trial: 29576307
Drug: MenACWY-TT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT vaccine (1 and 2 doses)
Trial: 29576307
Drug: MenACWY-TT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT vaccine (2 doses)
Trial: 22438232
Drug: Ciclesonide (507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide (507 μg/d)
Trial: 22438232
Drug: Control (202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (202 μg/d)
Trial: 18671773
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone and intranasal budesonide for 2 weeks, plus intranasal budesonide for 10 additional weeks
Trial: 12477601
Drug: THC 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC 0.15 mg/min
Trial: 12477601
Drug: THC 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC 0.25 mg/min
Trial: 12477601
Drug: THC (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (high dose)
Trial: 7776110
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of synthetic surfactant
Trial: 7776110
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of synthetic surfactant